InvestorsHub Logo
icon url

ABCtrader1027

08/03/12 8:00 PM

#208774 RE: Psionic Trader #208773

break out so big... needs proactive
icon url

Jacc

08/03/12 11:13 PM

#208780 RE: Psionic Trader #208773

lol @ the picture.....Im signed up though, got referred to you. let's see what you got!
icon url

The Night Stalker

08/04/12 3:49 PM

#208800 RE: Psionic Trader #208773

FRCN 10 Bagger+ here imo



FRCN Security Details
Share Structure
Market Value1 $373,082 a/o Aug 03, 2012
Shares Outstanding 82,907,073 a/o May 10, 2012
Float Not Available
Authorized Shares 200,000,000 a/o Jun 30, 2011
Par Value No Par Value

icon url

Abondanceinvest

08/06/12 9:30 AM

#208896 RE: Psionic Trader #208773

Gm$ Immunovative Inc (IMUOTC$5,000,000_equity_private_placement
Immunovative Inc (IMUN-OTC) has today announced that it has successfully completed a $5,000,000 equity private placement with a combination of institutional and accredited individual investors. The proceeds from this offering will be used for general and administrative purposes ("G & A"), specifically to accelerate several of the Company's key initiatives including providing financial support for Immunovative Therapies, Ltd. (“ITL”) to conduct a PIVOTAL Phase II/III clinical trial designed to demonstrate efficacy and safety in support of ITL’s lead Licensed Product called “AlloStim™” (“The Pivotal Trial”).

Antonio Treminio, CEO of IMUN, stated: “The Company is pleased to have completed this important round of financing. Our investors include high net worth individuals and prominent institutional investors. These proceeds will be used to accelerate the growth of IMUN and its clinical trials. Based upon the success of this initial raise, we believe we are well poised to raise the additional capital which should allow IMUN to merge with ITL and start our application process for NASDAQ listing. On behalf of our employees and affiliates, we wish to thank our investors and shareholders for their support and confidence in helping us build our dynamic company.”

Immunovative Inc. has developed an innovative treatment for cancer. Essentially, they have developed an effective way to help the human immune system fight cancer. Cancer treatments usually rely on chemotherapy which as we know has very severe side effects that cause serious problems. In trials Immunovative’s treatment has shown very positive results while side effects were very minor, such things as minor flew symptoms and rashes were reported.

It is believe to be a truly great advancement in the fight against Cancer. We are very excited to follow this opportunity; street momentum is building for this inspiring and dedicated young company.



We have included the link to the website which contains a wealth of information:

Website:

http://www.imun.com/

Recent Press Releases:

2012-08-06 Immunovative, Inc. Completes $5,000,000 Private Placement with Institutional and Accredited Individual Investors-

http://www.stockwatch.com/News/Item.aspx?bid=U-i0916645-U%3aIMUN-20120806&symbol=IMUN®ion=U

2012-07-31 Immunovative, Inc. Announces the Retention of Winston & Strawn LLP as Its Legal Counsel -

http://www.stockwatch.com/News/Item.aspx?bid=U-i0914646-U%3aIMUN-20120731&symbol=IMUN®ion=U

2012-07-31 Immunovative, Inc. (OTCBB: IMUN) Launches Corporate Site and ImmuNews Monthly Newsletter –

http://www.stockwatch.com/News/Item.aspx?bid=U-i0914694-U%3aIMUN-20120731&symbol=IMUN®ion=U

2012-07-30 Immunovative, Inc. Announces Launch of Website and Newsletter: ImmuNews

http://www.stockwatch.com/News/Item.aspx?bid=U-i0914416-U%3aIMUN-20120730&symbol=IMUN®ion=U

2012-07-27 Immunovative, Inc. Announces Formation of a Business Advisory Board and the Appointment of Bruno Vanderschelden as Chairman

http://www.stockwatch.com/News/Item.aspx?bid=U-i0913840-U%3aIMUN-20120727&symbol=IMUN®ion=U

For more press releases please visit Immunovative’s press release section on their website. http://www.imun.com/pressrelease.html







For more information please contact:

Mr. Antonio Treminio

Chairman & Chief Executive Officer

Immunovative, Inc.

New York: +1-212-315-9705

Montreal: +1-514-840-3697

Email: atreminio@imun.com



Mr. Seth M. Shaw

Vice President, Strategic Planning

Immunovative, Inc.

New York: +1-917-796-9926

Montreal: +1-514-840-3698

Email: sshaw@imun.com

icon url

NITE/$TOCKER

08/06/12 10:09 PM

#209017 RE: Psionic Trader #208773

AOXY...Crushed pennyland 2day!!!893% rumors of promotion soon